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Purpose: X-linked retinoschisis (XLRS) is a recessively inherited disorder that causes macular degeneration and resultant
visual defect in young males. Many genetic studies had focused on the patients in Western countries. We characterized
the mutational spectrum of the RS1 gene in Korean patients with XLRS, and aimed to provide genetic information of
XLRS in an Asian population.
Methods: This study enrolled 17 unrelated probands and their mothers for molecular genetic evaluation. All exons and
the flanking intronic regions of RS1 were analyzed by direct sequencing. We performed gene dosage analysis by
semiquantitative multiplex PCR to rule out the possibility of duplication in a patient without a sequence variation. We
also tried RT–PCR analysis in a case with a putative splicing mutation.
Results: Genetic tests revealed 16 Korean patients (94.1%) had RS1 mutations. In one patient, neither sequence variation
nor deletion or duplication in RS1 was detected. One case with de novo mutation was confirmed by familial analysis.
Identified were 14 causative mutations, three of which were novel: one missense mutation (c.227T>G, p.V76G) and two
splice-site mutations (c.78+1G>T and c.78+5G>A). No obvious genotype-phenotype relationship was observed.
Conclusions: A missense mutation was the predominant type, and common or founder mutations were not observed in
the Korean patients in this study who had XLRS. This study provides molecular genetic characteristics about an Asian
population previously unexplored. The genetic characteristics of Korean XLRS will be helpful for understanding the
worldwide spectrum of RS1 mutation.
X-linked  retinoschisis  (XLRS;  OMIM  312700)  is  a
recessively  inherited  bilateral  vitreoretinal  dystrophy  that
appears early in life, often in infancy [1]. The major symptom
of affected males is reduced visual acuity [2]. Examination by
ophthalmoscopy  or  optical  coherence  tomography  usually
reveals bilateral foveal schisis of variable degrees in retina.
Other  findings  include  peripheral  retinoschisis,  vitreous
changes, and a characteristic selective reduction of the b wave
of the electroretinogram [3]. Clinical presentation and disease
severity  can  vary  among  patients,  although  the  clinical
diagnosis  of  XLRS  is  based  on  fundus  abnormality,
electrophysiological findings, and family histories that are
consistent with X-linked inheritance [4].
Retinoschisin  1  (RS1),  the  only  gene  known  to  be
associated with XLRS, is located in Xp22.2-p22.1. It spans
approximately 15 kb, consists of six exons, and encodes a
24  kDa  protein  called  retinoschisin  [5,6].  This  protein
contains an evolutionarily conserved discoidin domain and
exists  as  an  octamer  in  which  subunits  are  joined  by
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intermolecular  disulfide  bonds  [7].  The  function  of
retinoschisin  is  unknown,  but  the  observation  that  other
members in the discoidin protein family are transmembrane
or secreted adhesion proteins suggests that retinoschisin may
also play a role in cell-to-cell adhesion [5,8].
Over 150 mutations in RS1 have been reported in the
Leiden open variation database for RS1. There are various
types  of  mutations,  but  the  majority  of  patients  harbor
missense mutations involving conserved amino acid residues
within the discoidin domain.
The  elucidation  of  mutation  in  various  ethnicities  is
essential  for  understanding  the  causative  gene  and  the
pathogenesis of XLRS. In previous studies, the distributions
of the RS1 mutation were found to differ among ethnicities.
Its worldwide prevalence ranges from 1:5,000 to 1:25,000
[9]. In Western countries, broad studies have been conducted.
In  Finland,  XLRS  is  prevalent  (>1:17,000),  and
approximately 95% of individuals of Finnish heritage have
one  of  three  founder  mutations  [10].  In  other  Western
countries, studies involving large numbers of patients have
shown heterogeneous mutation distribution without founder
effect [11-14]. Reports describing the mutation spectrum in
Asians have focused on relatively small numbers of probands.
In Japanese patients, familial studies of three to 14 pedigrees
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833[15-17] or studies of four to 11 unrelated patients [18-20]
revealed  that  heterogeneous  RS1  aberrations  were
predominantly  missense  mutations.  In  Chinese  patients,
studies of 12 families [21] or five probands [22] also showed
heterogeneous  missense  and  small  deletion  mutations.
However,  in  Koreans,  only  one  XLRS  family  has  been
confirmed  by  molecular  genetic  diagnosis  [23],  and  the
prevalence and spectrum of RS1 mutation were not known.
Therefore, a genetic study in Koreans as another Asian
population will provide more information about worldwide
RS1  mutations.  The  current  study  aimed  to  identify  the
molecular genetic characteristics of XLRS in Koreans through
more  comprehensive  analyses.  We  first  performed  exon
duplication study in a case without sequence variation, and
tried  reverse-transcriptase  PCR  (RT–PCR)  in  a  case  with
putative splicing mutation.
METHODS
Patients:  This  study  included  17  unrelated  Korean  male
patients  and  their  mothers.  Patients  had  visited  outpatient
clinics  in  Seoul  National  University  Hospital  or  Seoul
National University Bundang Hospital, with complaints of
decreased visual acuity or strabismus. All patients were giving
the diagnosis of XLRS by pediatric ophthalmologists (Y.S.Y.
and J.M.H.), and an experienced retinal specialist (K.H.P.).
Diagnosis was made primarily based on the presence of foveal
schisis (stellate pattern of microcystic schisis cavities in the
macula, Figure 1A), and peripheral schistic retinal changes
were  also  evaluated  with  meticulous  indirect
ophthalmoscopic examination and slit lamp biomicroscope. If
possible  and  affordable,  other  ancillary  tests  including
electroretinography,  optical  coherence  tomography,  or
fluorescein angiogram (for confirming no leakage from cystic
macular lesions), were performed to confirm the diagnosis
(Figure  1).  Two  of  the  patients  had  siblings  with  similar
symptoms.  Fifty-four  female  volunteers  were  recruited  as
normal controls after medical and ophthalmic examinations
at  the  Health  Promotion  Clinic.  The  study  protocol  was
approved by the institutional review board. All patients and
their mothers gave their consent to participate in this study.
Mutation analyses:
DNA extraction and XY sex determination—Whole
blood  samples  were  obtained  by  venipuncture  with
anticoagulant  EDTA  tubes.  They  were  stored  in  room
temperature, and genomic DNA was extracted within 48 h
using  the  PureGene  DNA  Isolation  kit  (Gentra  Systems,
Minneapolis,  MN).  Genetic  sex  determination  of  all
participants was done by amplifying the zinc finger protein,
X-linked gene (ZFX), and the zinc finger protein, Y-linked
gene  (ZFY).  PCR  products  were  then  digested  with  the
restriction enzyme HaeIII [24], and electrophoresed on 2.0%
(w/v) agarose gels.
Direct  sequencing  of  RS1—To  detect  sequence
variations in all six exons and their flanking intronic regions,
we designed primers (Table 1) and amplified RS1 by PCR.
The reaction was performed in a 20 μl volume containing 1X
PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 50 ng of DNA,
8 pmols of each primer, and 0.5 U of AmpliTaq Gold (Applied
Biosystems, Foster City, CA). The cycling profiles were as
follows: 95 °C for 10 min, 35 cycles of 30 s at 95 °C, 30 s at
each annealing temperature, and 1 min at 72 °C. The final
extension was at 72 °C for 7 min. PCR products were purified
by  ExoSAP-IT  treatment  (USB,  Cleveland,  OH)  and
bidirectionally sequenced on an ABI Prism 3730xl Genetic
Analyzer (Applied Biosystems) using a BigDye Terminator
Cycle Sequencing Ready Reaction Kit (Applied Biosystems).
Obtained  sequences  were  analyzed  using  Sequencher
software ver 4.6 (Gene Codes Corporation, Ann Arbor, MI).
Gene dosage analysis of RS1—The gene dosage of RS1
was assessed by semiquantitative multiplex PCR to detect
duplication. Six exons of the RS1 gene were amplified with the
HBB  gene  and  the  B2M  gene  as  endogenous  references.
Primer sequences are listed in Table 1. All of the forward
primers were labeled with 6-FAM. After 18 cycles of PCR,
the products were analyzed by ABI Prism 3130xl Genetic
Analyzer (Applied Biosystems) with the GeneMapper ID 3.7
software. The peak height ratio of each exon of a patient was
calculated by dividing the peak height of the RS1 gene by that
of the reference gene. Normalized dosage was determined by
using the following equation:
Gene dosage = Peaktarget(patient)/Peakreference(patient) /
Peaktarget(control)/Peakreference(control)
the peak height ratio of each exon of a patient was divided by
the  ratio  of  a  normal  male  control  tested  in  parallel.
Normalized  values  of  RS1  between  0.8  and  1.2  were
considered as one copy of the exon, and between 1.8 and 2.2
as two copies. Healthy females with two X chromosomes used
as two-copy controls of the RS1 gene, in compared to males
with one copy of RS1.
Significance assessment of novel mutations:
Allele  frequency  and  in  silico  analysis—Normal
frequency of novel sequence variation was determined in 108
normal  X  chromosomes  by  direct  sequencing.  We  used
Polymorphism  Phenotyping  (Polyphen)  and  Sorting
Intolerant From Tolerant (SIFT) software programs to predict
whether the novel missense mutation would affect protein
function.  Predictions  were  based  on  the  position-specific
independent counts (PSIC) score difference in Polyphen, and
the tolerance index in SIFT [25,26]. The effect of a novel
missense  mutation  was  also  assessed  by  the  degree  of
interspecies  amino  acid  conservation  using  the  software
Alamut. We also evaluated the effect of a putative splicing
mutation  by  GeneSplicer,  MaxEntScan,  and
SpliceSiteFinder-like using Alamut software.
RT–PCR  trial  in  the  case  with  a  putative  splicing
mutation—RT–PCR was performed to confirm the effect of
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834a novel putative splicing mutation, c.78+5G>A. Total RNA
was isolated from leukocytes or lymphoblastoid cell lines of
the  patient  using  the  RNeasy  mini  kit  (Qiagen,  Hilden,
Germany).  RT–PCR  was  performed  using  the  Omniscript
reverse transcriptase kit (Qiagen) and random hexamer or
downstream primers. To detect minute amounts of aberrantly
Figure 1. Ocular findings in a Korean XLRS patient (case 16). A: Fundus photograph of the both eyes showed typical stellate pattern of schisis
cavities in the macula. The inset presents an image of the macula magnified twofold. B: Fluorescein angiogram showed no definite leakage
from the cystic cavities. C: Optical coherence tomography showed the schisis in the nerve fiber layer. D: Electroretinogram showed markedly
decreased amplitude of b-wave and relative preservation of a-wave, which are key features of XLRS.
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835spliced  RNA,  we  also  used  the  whole  transcriptome
amplification  kit  (QuantiTect,  Qiagen)  with  oligo(dT)15,
random hexamer, or downstream primers. Primer sequences
are shown in Table 2.
Paternity test for the de novo mutation—To confirm
the de novo mutation, we performed paternity tests in the
proband  and  his  parents.  This  was  done  by  using  the
AmpFlSTR  profiler  plus  PCR  amplification  kit  (Applied
TABLE 1. PRIMERS FOR THE RS1 MUTATION ANALYSIS.
Gene Usage Exon Primer (5′→3′)
RS1 PCR and sequencing 1 F: GGTTAACTTGATGGGGCTCA
R: CCCATCCTGTTTTCTGTTGG
2 F: TTCTTCCAGAAGGGGTGTTG
R: AAGCGATTCTCTTGCCTCAG
3 F: TCAATTTGGCCATTGTAGCA
R: GGAGAAAACCCGCATTAACA
4 F: TGAACCGTTGAAGACACAGC
R: AGTGCAGTGGTGTGATCTCG
5 F: TTTCTTGGGAGGTGGAGATG
R: GCAGATGATCCACTGTGCTG
6 F: GTTCCAGATGTCCCAAGCAT
R: TGCGAAATATAGCCCTGTCC
RS1 Gene dosage 1 F: GGGAAGATGTCACGCAAGAT
R: AACTGGAAAGCCATCCACAC
2 F: GCCACATTGGGATTATCGTC
R: TGTTGGGATTACAGGCATGA
3 F: AACCACAGTTGCCTTTGACC
R: TGTTCCCAATGACTGTTCCA
4 F: CAGTCACCTGGTGCTTGTTG
R: CGAAGAATACCAGCCCACAT
5 F: TTTCTTGGGAGGTGGAGATG
R: TGTCCTGGAACTTGGAGAGC
6 F: GTTCCAGATGTCCCAAGCAT
R: GGTCCGAGTTGCCATAGAAG
HBB Gene dosage 2 F: TTGGACCCAGAGGTTCTTTG
R: GAGCCAGGCCATCACTAAAG
B2M Gene dosage 2 F: CTCACGTCATCCAGCAGAGA
R: AGTGGGGGTGAATTCAGTGT
Forward and reverse primers sequences were used to amplify the RS1, HBB, and  B2M  genes. Forward primers for gene dosage
analysis were labeled with 6-FAM. Annealing temperature was 55 °C, with exception of RS1 primers for amplification of exon
2 (60 °C), exon 4 (60 °C), and exon 5 (58 °C).
TABLE 2. PRIMERS FOR RT–PCR OF THE RS1 GENE.
Primer location Range Name Sequence (5′->3′)
RNA amplification
Retina Blood
Exon 1 and 2 Exon 2–4 93F GCCACATTGGGATTATCGTC successful successful
Exon 4                                 4aR             GAAGAATACCAGCCCACAT
Exon 1 Exon 1–6 36F GGGAAGATGTCACGCAAGAT successful failed
Exon 6                                 6R               GTCCGAGTTGCCATAGAAG
Exon 1 Exon 1–6 48F CGCAAGATAGAAGGCTTTTTG successful failed
Exon 6                                 6R               GTCCGAGTTGCCATAGAAG
Three primer pairs were designed to assess the effect of novel putative splicing mutation c.78+5G>A.
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836Biosystems). We analyzed ten genetic marker loci by using
the software GeneMapper ID 3.7 (Applied Biosystems).
Genotype-phenotype analysis: The possible relationship of
genotype and phenotype was assessed between the type of
mutation (missense versus intronic mutations) and clinical
characteristics  (age  at  symptom  detection,  coexistence  of
peripheral schisis, and comorbidity of vitreous hemorrhage)
with the Fisher's exact test or the Mann–Whitney test. The
possible effect of the changed amino acid (arginine versus
others)  was  also  analyzed  in  relation  with  clinical
characteristics.  Analyses  were  performed  with  SPSS  for
Windows version 12.0 (SPSS Inc., Chicago, IL). In each test, a
p-value  of  less  than  0.05  was  considered  statistically
significant.
RESULTS
Clinical  characteristics  of  patients:  The  clinical
characteristics  of  patients  enrolled  in  this  study  are
summarized in Table 3. The age of probands at the time of
diagnosis varied from one month to 14 years. The mean age
at diagnosis was 4.2±3.3 years. The initial presentation was
poor  visual  acuity  in  older  patients  (5.8±3.0  years,  11
probands) or strabismus detected by their parents in younger
patients  (1.6±1.3  years,  five  probands).  A  one-month-old
patient  (case  13),  born  prematurely,  had  bilateral  foveal
schisis. All patients showed typical honeycomb appearance
(foveal schisis) in the macula, and 82.4% of the probands also
harbored peripheral schisis. Peripheral schisis was bilateral in
70.6% of the probands. In three patients with no schisis in
periphery, two showed abnormal sheen in the inferior region
of the retina (case 3 and case 9). Vitreous hemorrhage was the
most  common  comorbidity  (41.2%).  Figure  1  shows
representative clinical findings of a patient (case 16).
Molecular diagnosis and mutational spectrum: Among the 17
Korean patients, 16 males (94.1%) harbored causative RS1
mutations and were given the diagnosis of XLRS based on
genetic tests. In these 16 patients, 14 kinds of mutations were
identified: 12 missense and two splice-site mutations. Three
mutations were novel: one missense mutation (c.227T>G,
p.V76G) and two splice-site mutations (c.78+1G>T and c.
78+5G>A;  Table  4  and  Figure  2).  Two  intronic
polymorphisms were also detected: c.184+35T>C and novel
c.184+129T>G.
A de novo mutation was found in one patient. Case 3 was
hemizygous for the p.C142W mutation, and neither parent had
this mutation. We confirmed the parent-child relationships
through paternity tests (data not shown).
Based on complete sequencing, one patient (case 13) with
bilateral foveal schisis harbored no DNA sequence variation.
By gene dosage analysis we revealed no RS1 gene dosage
alteration in this case (Figure 3), thus confirming that neither
sequence variation nor duplication/deletion was the cause of
his disease phenotype.
The most frequent cause of XLRS in Korean patients was
the missense mutation (14/16; 87.5% of total mutation). All
missense  mutations  identified  in  this  study  were  located
within  the  discoidin  domain  of  retinoschisin.  Contrary  to
previous reports of exon 4 as the site of highest mutation rate
[3], exon 6 of the RS1 gene was the most frequently involved
region in Koreans (8/14). Two intronic mutations were located
in intron 2. There was no predominant single mutation in
Koreans. Each of two mutations, p.E72K and p.R182C, was
found in two probands. The mutations in codon 72 (p.E72K
and p.E72Q) were identified in three unrelated probands. The
p.R182C  mutation  was  linked  to  two  polymorphisms,  c.
184+35T>C and c.184+129T>G, in two probands and their
mothers.
Significance  assessment  of  novel  mutations:  The  novel
missense mutation, p.V76G, was expected to cause XLRS:
The allele frequency was 0% in the normal control group. In
the p.V76G mutation, the nonpolar amino acid valine was
substituted by the smaller nonpolar glycine. This substitution
was predicted to be harmful to protein function by in silico
analysis. The tolerance index by SIFT was 0.00, which was
below the cutoff (<0.05) score of a deleterious substitution.
The PSIC score difference by Polyphen was 2.264, which was
above the cutoff (>2.0) score of probably damaging. Codon
76 of retinoschisin is highly conserved in human and other
species.  Amino  acid  valine  is  at  this  position  in  Pan
troglodytes,  Macaca  mulatta,  Rattus  norvegicus,  Mus
musculus,  Oryctolagus  cuniculus,  Canis  familiaris,  Bos
taurus,  Gallus  gallus,  Xenopus  tropicalis,  Tetraodon
nigroviridis, and Danio rerio. Isoleucine is only found in
Monodelphis domestica.
One  novel  splice-site  mutation,  c.78+1G>T,  was  a
definite causative mutation of XLRS. The allele frequency
was 0% in normal controls, and the substitution within the
invariant GT at the 5′ splice donor site was expected to block
normal  splicing.  A  different  mutation  involving  the  same
nucleotide  sequence  was  previously  reported  in  human
patients [27]. Another substitution in the same splice donor
site of intron 2 activated a cryptic splice site in a murine model
[28].
Another  splice-site  mutation,  c.78+5G>A,  was  also
predicted  to  be  causative.  Its  allele  frequency  was  0%  in
normal  controls.  In  the  prediction  software,  c.78+5G>A
introduced no alternative splice donor site. To determine the
effect of this novel variant, we performed RT–PCR by using
total  RNA  extracted  from  blood  leukocytes  and
lymphoblastoid  cell-lines.  The  RS1  RNA  was  reliably
detected in tissues of normal human retina with three different
pairs of primers (Table 2). However, only a scarce amount of
illegitimate  RS1  transcripts  was  detected  in  peripheral
mononuclear cells using a pair of primers targeted between
exon 1–2 junction and exon 4 (93F and 4aR), and two other
primer pairs (36F and 6R, 48F and 6R) for amplifying between
Molecular Vision 2009; 15:833-843 <http://www.molvis.org/molvis/v15/a86> © 2009 Molecular Vision
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838exon 1 and exon 6 did not work. There was no detectable RS1
transcript in cDNA amplified using a whole transcriptome
amplification kit. Even though the abnormal splicing product
of c.78+5G>A could not be detected in peripheral cells, we
predicted that this nucleotide change was pathogenic based on
its normal frequency, the phenotype of the patient, and a
genetic study of the mother.
Genotype-phenotype correlation: Clinical phenotypes were
not significantly different between patient group harboring
missense  mutations  versus  group  harboring  intronic
mutations: age at symptom detection (Mann–Whitney test,
p=0.267),  presence  of  vitreous  hemorrhage  as  an  ocular
comorbidity (Fisher's exact test, p=1.000), and coexistence of
peripheral  schisis  (Fisher's  exact  test,  p=1.000).  Clinical
manifestations  were  not  significantly  different  between
patient  group  harboring  missense  mutations  involving
arginine  versus  group  harboring  mutations  not  involving
arginine:  age  at  symptom  detection  (Mann–Whitney  test,
p=0.573) and presence of vitreous hemorrhage as an ocular
comorbidity (Fisher's exact test, p=0.138). The relationship
was also insignificant between the group harboring mutations
involving arginine and the coexistence of peripheral schisis
(Fisher's exact test, p=0.055). However, the possibility could
not be completely excluded that more large studies would
reveal the significance of arginine mutations.
DISCUSSION
In this study, we identified the mutation spectrum in Korean
patients  clinically  diagnosed  with  XLRS.  In  94.1%  of
probands, we detected known RS1 gene mutation or novel
genetic  variation  suspected  as  deleterious.  No  obvious
genotype-phenotype association was observed in the Korean
patients we studied.
Missense mutation in the discoidin domain is the major
type of causative mutation in Korean patients. Any amino acid
TABLE 4. MUTATIONS AND POLYMORPHISMS IDENTIFIED IN THE KOREAN XLRS PATIENTS
Nucleotide change Location Effect of change Case Previous report
c.78+1G>T Intron 2 Splicing mutation Case 4 Novel mutation
c.78+5G>A Intron 2 Splicing mutation Case 8 Novel mutation
c.184+35T>C Intron 3 Polymorphism Case 12, 14 Leiden open variation database for RS1
c.184+129T>G Intron 3 Polymorphism Case 12, 14 Novel variant
c.214G>A Exon 4 p.E72K Case 9, 16 [11]
c.214G>C Exon 4 p.E72Q Case 15 [36]
c.227T>G Exon 4 p.V76G Case 6 Novel missense mutation
c.305G>A Exon 4 p.R102Q Case 7 [11]
c.426T>G Exon 5 p.C142W Case 3 [37]
c.544C>T Exon 6 p.R182C Case 12, 14 [11]
c.589C>T Exon 6 p.R197C Case 2 [11]
c.590G>A Exon 6 p.R197H Case 1 [11]
c.625C>T Exon 6 p.R209C Case 11 [11]
c.637C>T Exon 6 p.R213W Case 17 [11]
c.638G>A Exon 6 p.R213Q Case 10 [15]
c.647T>C Exon 6 p.L216P Case 5 [11]
Figure 2. Sequences of three novel mutations identified in this study. A: c.78+1G>T was found in case 4. B: c.227T>G (p.V76G) was found
in case 6. C: c.78+5G>A was found in case 8. The upper and lower panels reveal the RS1 sequences of three probands and mothers, respectively.
All three patients inherited the novel variants from their mothers. Positions of novel variants are indicated by arrows.
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839codon  was  not  predominant  for  causative  mutation  in
retinoschisin.  In  previous  studies  of  different  ethnicities,
mutation  spectrums  were  variable:  p.E72K  was  the  most
common mutation in Western populations [11]. Among the
Finnish patients, p.E72K mutation was in 70%, and p.G109R
was in 19% [10]. However, no common mutation has been
reported  in  Japanese  or  Chinese  patients  [15-21].  In  the
Korean  population,  a  previously  undefined  ethnicity,
mutation p.E72K  was found in only two probands in this
study. The dramatic mutational difference in Korean versus
Finnish patients suggests that the mutation spectrum of Asian
population may be different from those of some Western
ethnicities. There was no apparent founder effect in Koreans,
but  the  linkage  between  the  p.R182C  mutation  and
polymorphisms  c.184+35T>C  and  c.184+129T>G  in  two
patients  and  their  mothers  suggested  the  possibility  of
haplotypes of XLRS in Koreans.
Through this study, three novel mutations were found in
the Korean population. Novel missense mutation p.V76G was
located in the discoidin domain of retinoschisin, a well known
region for causative mutations in XLRS. Two novel splice site
mutations, c.78+1G>T and c.78+5G>A, were suspected to
affect normal structure of protein. Each novel mutation was
unique in each proband and his family. All three probands
showed abnormalities indistinguishable from other Korean
XLRS patients. These novel mutations widen the mutational
spectrum of RS1 and expect to help diagnosis of rare genetic
disease XLRS in Asians or other ethnicities.
Previously, cysteine has been recognized as a residue
frequently involved in RS1 mutation. Even numbers of ten
cysteine residues are present in retinoschisin, and the protein
forms intermolecularly disulfide-bridged octamers, which are
necessary  for  its  biologic  function  [7].  Consequently,  the
sequence variant that changes the total cysteine number in
retinischisin is considered a definite causative mutation. In
this study, four sequence changes (4/12 missense mutation)
involved  cysteine  residues,  introducing  loss  or  gain  of  a
cysteine  in  retinoschisin.  Interestingly,  seven  sequence
changes involved arginine residues in 12 missense mutations.
All of these sequence changes resulted in loss of an arginine.
This mutation rate seemed higher than those reported in other
large  studies  of  XLRS  [11,12]  or  those  of  other  genetic
diseases. Arginine is a well known mutated residue in proteins
[29], and mutations at arginine residues account for almost
15% of the genetic disease mutations [30]. However, one
previous report about XLRS also indicated frequent arginine
involvement [13], and the role of some arginine residues in
the structure of retinoschisin has been suggested in previous
studies  [31,32].  Therefore,  the  cause  of  apparently  high
mutability of arginine in this study and the effect of arginine
mutation  in  XLRS  need  to  be  elucidated  through  further
studies.
A proband with de novo mutation was found in this study.
A de novo mutation is rare in XLRS. We confirmed de novo
mutation  through  familial  genetic  tests.  However,  the
possibility of germline mosaicism within the mother should
be considered in subsequent genetic counseling and prenatal
diagnosis.
One patient (case 13) in this study showed bilateral foveal
and peripheral schisis indistinguishable from XLRS, but had
Figure  3.  The  representative
chromatograms of gene dosage PCR. A:
A normal female has two copies of the
RS1. B: A normal male has one copy of
the RS1. C: The chromatogram of case
13 showed one copy of the RS1. Each
amplified products from six exons of
RS1 is indicated by the arrowhead above
the fluorescent peak, and the size of each
amplicon  is  shown  below.  The  ratio
calculated from the height of each peak
is  proportional  to  the  targeted  exon
dosage,  therefore  duplication  can  be
ruled out in the case 13. For example,
the  gene  dosage  of  exon  4  was
calculated as 1.0 in normal male, 2.09 in
normal  female,  and  1.05  in  case  13.
Abbreviations:  beta  hemoglobin  gene
(HBB);  beta-2-microglobulin  gene
(B2M).
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840no  sequence  variation  within  the  RS1  gene.  It  has  been
reported  that  no  sequence  alteration  was  found  in
approximately  10%  of  patients  clinically  compatible  with
XLRS [11,33]. In these patients, another cause of observed
abnormalities should be considered such as other diseases
than  XLRS,  or  other  genetic  aberrations  than  sequence
variation in the RS1 gene. Clinically, the possibility could not
be completely excluded, but least likely, that his comorbid
condition such as premature birth had caused his schistic
change,  intra-schitic  and  vitreous  hemorrhage,  and
electroretinographic  findings.  Genetically,  deletion  or
duplication is one of the possible forms in the molecular
genetic pathogenesis. Each exonal dosage test in the RS1 is a
novel  diagnostic  approach  in  cases  with  compatible
phenotype  of  XLRS  and  with  no  sequence  variation.
Intragenic  deletion  was  excluded  in  this  case  because  of
successful sequence amplification. Therefore we developed a
gene dosage PCR, applied it to the case 13, and confirmed the
absence of duplication within the RS1. Thus, in the clinically
compatible,  mutation-negative  XLRS  patients  by  direct
sequencing, alternative approaches may be required: not only
the gene dosage PCR successfully developed in this study but
also future investigations such as analyses of the promoter
regions, or search for other loci.
Existing in silico software can predict the consequence
of a missense mutation in a protein [26]. Although not accurate
enough, such programs are frequently used as an important
tool.  Novel  missense  mutation  p.V76G  was  predicted  by
software to be harmful to protein structure and function. Two
novel intronic variations, c.78+1G>T and c.78+5G>A, were
also suggested as causative mutations of XLRS, given the
phenotypes of the probands. The mutation in the invariant GT
of a splice donor, c.78+1G>T, was a definite cause of XLRS.
The novel change, c.78+5G>A, located slightly away from
the exon-intron boundary, was suspected to affect splicing.
The lack of the RS1 gene transcript in blood cells has been
reported  since  the  1990s.  Transcripts  of  RS1  have  been
detected in only a few organs outside retina such as human
uterus [34] and pineal gland [35]. In this study, we detected
the scarce amount of illegitimate transcription of RS1 gene in
blood cells. Although we found no working primer to detect
abnormally spliced mRNA due to variant located intron 2, the
effect of splicing variant could potentially be demonstrated
experimentally under optimized conditions. Further work is
required to explore the splicing variant in RS1.
In  this  study,  no  significant  genotype-phenotype
relationship was observed. Previous study about Caucasians
showed no correlation between mutation type and severity of
disease [12]. In Asian populations, no obvious association had
been demonstrated in relatively small groups of Japanese or
Chinese patients [15,20,22]. Phenotypic variability within the
same genotype had been also noted in Japanese patients [16],
and a few studies had implied the possibility of genotype-
phenotype  relationship:  complication  such  as  retinal
detachment was apparently frequent in exonal deletion or
p.R182C mutation in Japanese [17]. Phenotypes of XLRS
were more severe in frameshift, splice site, or some missense
mutations  in  Chinese  [21].  The  possibility  of  genotype-
phenotype  correlation  and  factors  causing  phenotypic
variation are still needed more investigations.
The limitation of this study is only limited numbers of
patients  were  performed  electroretinogram  and  optical
coherence  tomography  that  might  help  to  confirm  the
diagnosis. However, all the patients have bilateral stellate
pattern of microcystic schisis cavities that was known as a
pathognomonic  sign  of  X-linked  retinoschisis.  82%  have
additional  peripheral  retinal  schisis  which  helps  to
differentiate with other diseases. Dominant cystoid macular
edema  usually  did  not  accompany  the  peripheral  retinal
schisis. No patient showed pigmentary degeneration of retina
and  nyctalopia  that  was  common  in  Goldmann-Favre
syndrome  and  retinitis  pigmentosa.  No  patient  showed
vitreous band or empty halo that might suggest the Sticker
syndrome,  Norrie  disease  and  familial  exudative
vitreoretinopathy.  No  ocular  inflammation  including  pars
planitis was observed in the patients. Optic disc abnormalities
such as congenital optic pit and morning glory syndrome were
also not observed. Even though we did not completely rule
out the other diseases mimicking X-linked retinoschisis, these
clinical findings were quite robust evidence to differentiate X-
linked retinoschisis from the other similar diseases.
The  importance  of  clinical  molecular  genetics  is
increasing.  Elucidation  of  the  mutation  spectrum  and
genotype-phenotype correlation contributes to the diagnosis
and treatment of genetic ocular diseases. This study identified
the genetic and clinical characteristics of XLRS in Koreans as
an  Asian  ethnicity  that  had  not  been  previously  studied.
Molecular techniques including gene dosage analysis were
applied in this study. These will be helpful for diagnosis of
XLRS and as confirmation when a clinical examination is
difficult or the manifestation is uncommon.
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